Protection

Understanding Valsartan’s Protective Benefits

Beyond its proven efficacy in lowering blood pressure, Valsartan offers broad cardiovascular protection¹ supported by clinical evidence. This section highlights key trials demonstrating its role in reducing the risk of different cardiovascular diseases, and supporting patients with high cardiovascular risk.

Explore how Valsartan extends its value beyond BP control to comprehensive heart health.

VALHEFT TRIAL

SVG	5,010 patients

For more details click here

VALUE TRIAL

SVG	15,245 patients

For more details click here

VALIANT TRIAL

SVG	14,703 patients

For more details click here

VALUE TRIAL

SVG	15,245 patients

For more details click here

NAVIGATOR TRIAL

SVG	9,518 patients

For more details click here

ACE-I: Angiotensin converting enzyme inhibitor

References

Egyptian drug authority Tareg approved leaflet; approval date: 26/10/2020.
Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heartfailure. New England Journal of Medicine. 2001 Dec 6;345(23):1667-75.
Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR, Laragh J, Schork MA, Hua TA,Amerena J, Balazovjech I. The valsartan antihypertensive long-term use evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension. 2006 Sep 1;48(3):385-91.
Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT,Mitchell L, Plat F. Outcomes in hypertensive patients at high cardiovascular risk treated with regimensbased on valsartan or amlodipine: the VALUE randomised trial. The Lancet. 2004 Jun 19;363(9426):2022-31.
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New England Journal of Medicine. 2003 Nov 13;349(20):1893-906.
NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. New England Journal of Medicine. 2010 Apr 22;362(16):1477-90

Approved by Egyptian Drug Authority: HF0082OA4758/102025. Invalidation date: 14/10/2027.
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg.